This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I or a physiologically acceptable salt or solvate thereof



I

in which

R^1, R^2 in each case independently of one another are aryl or Het,

aryl is phenyl which is unsubstituted or mono-, di-, or trisubstituted by

Hal, CN, A, OA, or OH,

Het is 2-furyl, 3-furyl, 2-thienyl, 3-theinyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or –5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or –5-yl, 1,2,4-oxadiazol-3- or –5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or –5-yl, 1,2,3-thiadiazol-4- or –5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4-H-thiopyranyl [sic], 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or

7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, benzo[1,3]dioxol-4- or -5-yl, benzo[1,4]dioxan-5- or -6-yl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,

~~is a a mono- or binuclear unsaturated heterocyclic ring system which is unsubstituted or mono- or di-, or trisubstituted by Hal, A, CN, OR or OH and which contains one, two or three identical or different heteroatoms such as nitrogen, oxygen an sulfur,~~

A is alkyl having 1-6 C atoms, and

Hal is F, Cl, Br, or I.

2. (Previously Presented) A process for the preparation of a compound of formula I, comprising reacting a compound of formula II

$$R^1\text{-}CH2\text{-}CH2\text{-}L \qquad II$$

in which L is Cl, Br, I or a free or relatively functionally modified OH group, and R^1 has the meaning indicated in claim 1,

with a compound of formula III



III

in which R2 and A have the meanings indicated in claim 1, or

b) reacting a compound of formula IV



IV

in which R^1 and R^2 have the meaning indicated in claim 1,

with a compound of the formula V

R-X-A V

in which R is iodine or bromine, X is Mg and A has the meaning indicated in claim 1, in a Grignard reaction, or

c) a compound of formula I ~~it~~ is liberated from one of its functional derivative by treating said derivative with a solvolysing or hydrogenolysing agent, or

d) a base of the formula I which is obtained is converted into one of its salts by treating with an acid.

3. (Previously Presented) A pharmaceutical composition comprising a compound of the formula I according to claim 1 and a pharmaceutically acceptable carrier.

4. (Cancelled)

5. (Withdrawn) A method for treating psychoses, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, premenstrual syndrome or a compulsive behaviour comprising administering to a host in need thereof a therapeutically effective amount of a compound according to claim 1.

6. (Cancelled)

7. (Withdrawn) A method for treating an indication which is mediated by a 5-HT_{2A} receptor, comprising administering a therapeutically effective amount of a compound according to claim 1 to a host in need thereof.

8. (Withdrawn) The method according to claim 7 wherein the indication is psychoses, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, bulimia, anorexia nervosa, premenstrual syndrome or obsessive compulsive disorder.

9. (Previously Presented) The compound according to claim 1, wherein said A is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, or 1,2,2-

trimethylpropyl.

10. (Previously Presented) The compound according to claim 1, wherein said OA is methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutosy, sec-butoxy, or tert-butoxy.

11. (Previously Presented) The compound according to claim 1, wherein said Aryl is phenyl, 0-tolyl, m-tolyl, p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-trifluoromethylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-trifluoromethoxyphenyl, o-, m- or p-cyanophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-difluor

omethoxyphenyl, o-, m- or p-fluoromethoxyphenyl, furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2-chloro-3-methyl-, 2-chloro-4-methyl-, 2-chloro-5-methyl-, 2-chloro-6-methyl-, 2-methyl-3-chloro-, 2-methyl-4-chloro-, 2-methyl-5-chloro-, 2-methyl-6-chloro-, 3-chloro-4-methyl-, 3-chloro-5-methyl- or 3-methyl-4-chlorophenyl, 2-bromo-3-methyl-, 2-bromo-4-methyl-, 2-bromo-5-methyl-, 2-bromo-6-methyl-, 2-methyl-3-bromo-, 2-methyl-4-bromo-, 2-methyl-5-bromo-, 2-methyl-6-bromo-, 3-bromo-4-methyl-, 3-bromo-5-methyl- or 3-methyl-4-bromophenyl, 2,5- or 3,4-dimethoxyphenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-tri-tert-butylphenyl, furthermore preferably 3,5-ditrifluoromethylphenyl, 2,5-dimethylphenyl, 2-hydroxy-3,5-dichlorophenyl, 2-fluoro-5- or 4-fluoro-3-trifluoromethylphenyl, 4-chloro-2- or 4-chloro-3-trifluoromethyl-, 2-chloro-4- or 2-chloro-5-trifluoromethylphenyl, 4-bromo-2- or 4-bromo-3-trifluoromethylphenyl, p-iodophenyl, 2,5-dimethoxy-4-nitrophenyl, 4-fluoro-3-chlorophenyl, 4-fluoro-3,5-dimethylphenyl, 2-fluoro-

4-bromophenyl, 2,5-difluoro-4-bromophenyl, 2,4-dichloro-5-methylphenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 2-methoxy-5-methylphenyl or 2,4,6-triisopropylphenyl.

12. (Cancelled)

13. (Previously Presented) The compound according to claim 1, wherein said R^1 is 2,3-dimethoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 2,3-2,4-, 3,4- or 2,6-difluorophenyl, 2- or 4-trifluoromethylphenyl, 2-, 3- or 4-tolyl, 2-chloro-6-fluorophenyl, 2-fluoro-4-trifluoromethylphenyl, 3-fluoro-5-trifluoromethylphenyl, 4-fluoro-6-trifluoromethylphenyl, 3-fluoro-4-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 4-cyanophenyl, thiophen-2- or 3-yl [sic], 5-chlorothiophen-2-yl, 5-methylthiophen-2-yl, 2,5-dichlorothiophen-3-yl, 2-chloro-3-methylthiophen-5-yl, bromothiophen-5-yl, 2-chloro-5-methylthiophen-4-yl, 2-methoxythiophen-5-yl, 2- or 4-methylthiazol-4- or -5-yl, and pyridin-4-yl.

14. (Previously Presented) The compound according to claim 1, wherein said R^2 is phenyl, 4-chlorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 4-trifluromethylphenyl, thiopheny-2-yl, 5-chlorothiophen-2yl, 2,5-dichlorothiophen-3-yl, benzodioxan-5-yl, or benzodioxan-6-yl.

15. (Previously Presented) The compound according to claim 1, wherein said compound is 1-{1-[2-(5-chlorothiophen-2 yl)ethyl]piperidin-4-yl}-1-(4-fluorophenyl)ethanol .

16. (Withdrawn) A method for treating psychoses, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, premenstrual syndrome or a

compulsive behaviour comprising administering to a host in need thereof a therapeutically effective amount of 1-{1-[2-(5-chlorothiophen-2 yl)ethyl]piperidin-4-yl}-1-(4-fluorophenyl)ethanol .

17. (Withdrawn) A method for treating an indication which is mediated by a 5-HT_{2A} receptor comprising administering to a host in need thereof a therapeutically effective amount of 1-{1-[2-(5-chlorothiophen-2 yl)ethyl]piperidin-4-yl}-1-(4fluorophenyl) ethanol .

18. (Withdrawn) A method for treating a functional disorder of the central nervous system comprising administering a therapeutically effective amount of a compound according to claim 1.

19. (Withdrawn) A method for treating inflammation comprising administering a therapeutically effective amount of a compound according to claim 1.

20. (Withdrawn) A method for treating brain and spinal cord trauma comprising administering a therapeutically effective amount of a compound according to claim 1.

Please add the following new claim:

--21. (New) A compound of formula I or a physiologically acceptable salt or solvate thereof



I

in which

R^1 is 2,3-dimethoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 2,3- 2,4-, 3,4- or 2,6-difluorophenyl, 2- or 4-trifluoromethylphenyl, 2-, 3- or 4-tolyl, 2-chloro-6-fluorophenyl, 2-fluoro-4-trifluoromethylphenyl, 3-fluoro-5-trifluoromethyl-phenyl, 4-fluoro-6-trifluoromethylphenyl, 3-fluoro-4-trifluoromethylphenyl, 2-fluoro-6-trifluoro-methylphenyl, 4-cyanophenyl, thiophen-2- or 3-yl [sic], 5-chlorothiophen-2-yl, 5-methylthiophen-2-yl, 2,5-dichlorothiophen-3-yl, 2-chloro-3-methylthiophen-5-yl, bromothiophen-5-yl, 2-chloro-5-methylthiophen-4-yl, 2-methoxythiophen-5-yl, 2- or 4-methylthiazol-4- or -5-yl, and pyridin-4-yl,

R^2 is phenyl, 4-chlorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 4-trifluromethylphenyl, thiopheny-2-yl, 5-chlorothiophen-2yl, 2,5-dichlorothiophen-3-yl, benzodioxan-5-yl, or benzodioxan-6-yl,

Hal, CN, A, OA, or OH,

A is alkyl having 1-6 C atoms, and

Hal is F, Cl, Br, or I .--